The markets are open, but its a federal holiday. The FDA is a government agency so I'm sure its closed Oct/14 so it makes sense for ATRS to receive the notice early.
I've got an opinion on AGEN but its not a positive one. I imagine Maxim upgraded since their looking to raise some funds for AGEN.
Nice find. I've been checking the website on a weekly basis for the update. ATRS has previously stated they could reveal the drugs identity once the Phase III started so maybe we'll get a PR.
HALO got screwed by the FDA, but the recent EMA approval should open the door for their partnered programs with big pharma. Its got proven technology but gets no respect from investors. Traders have controlled the stock price & made a fortune playing the swings. Sell the pop & buying the dip.
If you just consider one drug, PEGPH20 then that alone is worth the current market cap. They recently reported a significant improvement in a Phase Ib trial for pancreatic cancer. This drug could be part of first line treatment for pancreatic as well as other cancers. Several Phase II trials have started & if they can report positive results (may take a few years) then I doubt they would even have to conduct a Phase III.
HALO could see another partnered drug approval this month in the EMA & they will report some phase II data this month on cellulite treatment. These could be significant catalysts.
I've sort of stayed away from their message board recently since the swing traders are trying to scare retail. I'm overweight the stock. Big pharma should make a play on the company, but I doubt they'd be interested.
They operate in secrecy, rarely have news, & have little interest in shareholders.
The only thing obvious is that a company can't introduce SQ methotrexate into the US market without clinical trials & filing an NDA. ATRS is the only company which will have done so.
I'm not doing much in the market right now other then watching my long plays. I made a few dumb trades this year so I'm punishing myself by working more.
What if you bought at $5.50 nine months ago how much of a gain would you have?
Mickelson couldn't have played any better or worse at the same time. The guy should have won by 10 strokes but he couldn't make a birdie put to save his life & he had a few dumb mistakes. What a disappointment.
I'm not missing any point. I made my money with ACAD. If ACAD doubles it has to trade for almost $40 & it will have a $3 billion market cap. For ATRS to double it has to trade for $8 & a billion market cap I just think the roads easier for ATRS to achieve that goal.
Your theory is illegal & makes zero sense.
As far as any new trials. The only one I've been watching is the Advil Gel. PFE needs to update the data base from not recruiting to recruiting. They were supposed to start the trial in May, but maybe they pushed it back a month.
I responded to your Atropine post yesterday so what more do you want?
I'd love to see the good guy win (Mickelson). Tiger's struggling with his swing & I wouldn't be surprised to see him withdraw since he's risking further injury.
Ok, say their right & Otrexup is only a $50 million annual drug. What they don't understand is that would be enough to make the company highly profitable. Add in the $20 million a year in royalties from the epi-pen starting in mid-2015, QST in 2016, & the bashers arguments don't work. ATRS has time on their side due to the low burn rate so just ignore the idiots except as entertainment.